Travere Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $47.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors that indicate a positive outlook for Travere Therapeutics. The FDA’s decision to cancel the AdCom meeting for FILSPARI’s sNDA in FSGS suggests confidence in the drug’s data, which is supported by strong results from the Phase 3 DUPLEX and Phase 2 DUET studies. These studies demonstrated significant reductions in proteinuria and long-term remission benefits, reinforcing the drug’s favorable safety profile.
Additionally, the recent update to the REMS labeling for FILSPARI, which reduces liver function monitoring and removes pregnancy monitoring requirements, is seen as a competitive advantage. This change eases the logistical burden on patients and prescribers, potentially increasing the adoption of FILSPARI in treating chronic conditions like IgAN. Despite mixed regulatory sentiment, these developments bolster confidence in FILSPARI’s market potential and Travere’s commercial execution, supporting the Buy rating.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $29.00 price target.